<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33408">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671708</url>
  </required_header>
  <id_info>
    <org_study_id>IDA+BUCY vs BUCY-AML-2016</org_study_id>
    <nct_id>NCT02671708</nct_id>
  </id_info>
  <brief_title>IDA+BUCY vs BUCY Conditioning Regimen for Low-risk and Intermediate-risk AML Undergoing Auto-HSCT</brief_title>
  <official_title>Idarubicin+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Low-risk and Intermediate-risk Acute Myeloid Leukemia Undergoing Autologous Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous hematopoietic stem cell transplantation (Auto-HSCT) is an effective alternative
      to allogeneic HSCT for low-risk and intermediate-risk acute myeloid leukemia (AML) without
      HLA-matched donors. At present, the best conditioning regimen for AML undergoing auto-HSCT
      remains in discussion. In this study, the safety and efficacy of IDA+BUCY and BUCY
      myeloablative conditioning regimens in low-risk and intermediate-risk AML undergoing
      auto-HSCT are evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Auto-HSCT is an effective alternative to allogeneic HSCT for low-risk and intermediate-risk
      AML without HLA-matched donors. BUCY conditioning regimen is the standard myeloablative
      regimen for AML undergoing auto-HSCT. However, auto-HSCT appears to have higher relapse rate
      but lower transplant-related mortality, compared with allo-HSCT. To reduce the relapse rate,
      IDA is added in the conditioning regimen. In this study, the safety and efficacy of IDA+BUCY
      and BUCY myeloablative conditioning regimens in low-risk and intermediate-risk AML patients
      undergoing auto-HSCT are evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>leukemia relapse rate</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplant-related mortality (TRM)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Autologous Hematopoietic Stem Cell Transplantation</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Conditioning</condition>
  <arm_group>
    <arm_group_label>IDA+BUCY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For low-risk and intermediate-risk AML undergoing auto-HSCT，IDA+BUCY conditioning regimen was IDA 15mg/m2/day on days -11 and -9；BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BUCY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For low-risk and intermediate-risk AML undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days
-3 and -2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin（IDA）</intervention_name>
    <description>Idarubicin was administered at 15mg/m2/day on days -11 and -9.</description>
    <arm_group_label>IDA+BUCY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan (BU)</intervention_name>
    <description>Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.</description>
    <arm_group_label>IDA+BUCY</arm_group_label>
    <arm_group_label>BUCY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (CY)</intervention_name>
    <description>Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.</description>
    <arm_group_label>IDA+BUCY</arm_group_label>
    <arm_group_label>BUCY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low-risk and intermediate-risk AML

          -  Achieving CR after one cycle induction,then receiving three cycles of consolidation
             therapy including moderate and high doses of Ara-c combined regimens

          -  With negative MRD before mobilization and collect of peripheral blood stem cells

          -  Without HLA-matched donors (related and unrelated)

        Exclusion Criteria:

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 30, 2016</lastchanged_date>
  <firstreceived_date>January 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
